Carbergoline for Antipsychotic Induced Hyperprolactinemia.

The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer : Is the severity of positive and negative symptoms affected by the use of cabergoline? Researchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups. Participants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.

NCT Number	NCT07386080
Lead Sponsor	Zealand University Hospital Collaborators: Region Zealand
Conditions	Scizophrenia
Enrollment	146 participants
Start Date	2026-05-01
Primary Completion	2028-05-01 (estimated)
Study Completion	2029-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-04